ANIKA ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Anika Therapeutics, Inc. for possible violations of federal securities laws and unlawful business practices, following a significant drop in stock price after the announcement of clinical trial results for Hyalofast [1][3]. Group 1: Company Overview - Anika Therapeutics, Inc. (NASDAQ: ANIK) is involved in the development of medical products, including Hyalofast, a resorbable hyaluronic acid scaffold for cartilage repair [3]. - The company recently announced topline results from a pivotal clinical trial, which indicated that while Hyalofast showed improvements in treated patients, it did not meet its pre-specified co-primary endpoints [3]. Group 2: Stock Performance - Following the announcement of the clinical trial results, Anika's stock price fell by $3.06 per share, representing a decline of 27.42%, closing at $8.10 per share on July 30, 2025 [3]. Group 3: Legal Investigation - Bragar Eagel & Squire, P.C. is encouraging investors who suffered losses due to the stock price decline to contact them to discuss their legal rights and options [1][4]. - The investigation is focused on whether Anika's actions may have constituted violations of federal securities laws [1].